High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM

The Company Also Reports Positive Free Cash Flow and Net Income

The Company's German Medical Cannabis Subsidiary, Remexian Pharma GmbH (Remexian) Generated Record Revenue of $31.6 Million with Gross Margins Increasing to 27%

• The Company Has Secured Credit Approval with Bank of Montreal for $40MM of Senior Secured Credit Facilities to Fuel Further Non-Dilutive Growth
• Canadian Cabana Club Membership Now Exceeds 2.65 Million, Up 39% Compared to the Previous Year
• ELITE Members in Canada Have Surpassed 178,000, Up 84% Compared to the Previous Year
• High Tide Remains the Highest Revenue Generating Cannabis Company Reporting in Canadian Dollars,1 and Continues to Hold a Leading 12% Share of the Cannabis Retail Market Across the Five Provinces in Which the Company Has a Presence2

CALGARY, AB, June 15, 2026 /PRNewswire/ – High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, today released its financial results for the second fiscal quarter of 2026 ended April 30, 2026, the highlights of which are included in this news release. The full set of unaudited condensed interim consolidated financial statements for the three months ended April 30, 2026 and 2025 (the "Financial Statements") and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.hightideinc.com, its profile pages on SEDAR+ at www.sedarplus.ca, and EDGAR at www.sec.gov/edgar.

High Tide Inc., June 15, 2026

if video/audio/not yotube

Remexian - Revenue & Gross Margin %

if video/audio/not yotube

Remexian - Tonnage Sold (Tonnes)

if video/audio/not yotube

Remexian - Market Share (3 Months Ended)

if video/audio/not yotube